• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by EyePoint Pharmaceuticals Inc.

    8/7/25 4:31:23 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $EYPT alert in real time by email
    S-8 1 eypt-20250807.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on August 7, 2025

    Registration No. 333-   

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    EyePoint Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

    26-2774444

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    480 Pleasant Street, Watertown, MA 02472

    (Address of Principal Executive Offices, including zip code)

    EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan

    Nonqualified Stock Option Awards (Inducement Grants)

    (Full title of the plans)

    Jay S. Duker, M.D.

    President and Chief Executive Officer

    EyePoint Pharmaceuticals, Inc.

    480 Pleasant Street

    Watertown, MA 02472

    (Name and address of agent for service)

    (617) 926-5000

    (Telephone number, including area code, of agent for service)

    Copies to:

     


     

     

     

     

    Stephen M. Nicolai, Esq.

    Hogan Lovells US LLP

    1735 Market Street, 23rd Floor

    Philadelphia, PA 19103

    (267) 675-4600

    Ron Honig, Esq.

    Chief Legal Officer & Company Secretary

    EyePoint Pharmaceuticals, Inc.

    480 Pleasant Street

    Watertown, MA 02472

    (617) 926-5000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

    EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan

    This Registration Statement on Form S-8 (the “Registration Statement”) registers an additional 2,900,000 shares of common stock of EyePoint Pharmaceuticals, Inc. (the “Registrant”), par value $0.001 per share (the “Common Stock”), available for issuance under the EyePoint Pharmaceuticals, Inc. 2023 Long Term Incentive Plan, as amended (the “2023 Plan”). The contents of the previous Registration Statements on Form S-8 filed by the Registrant with the U.S. Securities and Exchange Commission (the “Commission”) for the 2023 Plan on October 20, 2023 and August 8, 2024 (File Nos. 333-275124 and 333-281393), to the extent not otherwise amended or superseded by the contents hereof, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

    Inducement Nonqualified Stock Option Awards

    This Registration Statement is also being filed for the purpose of registering 660,700 shares of Common Stock issuable upon the exercise of nonqualified stock option awards granted to employees of the Registrant to induce each such employee to accept employment with the Registrant in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Awards”). The Inducement Awards were approved by the Registrant’s Compensation Committee of the Board of Directors in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4). The Inducement Awards were granted outside of the Plans.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    As permitted by the rules of the Commission, this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the Plans or Inducement Awards, as applicable, as required by Rule 428(b)(1) under the Securities Act of 1933, as amended.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:

    (a) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 6, 2025 (including those portions of the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 28, 2025, that are incorporated by reference into Part III of such Annual Report on Form 10-K);

     

    (b) the Registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, filed with the Commission on May 8, 2025, and June 30, 2025, filed with the Commission on August 7, 2025;

    (c) the Registrant’s Current Reports on Form 8-K, filed with the Commission on January 8, 2025, January 13, 2025 (except Item 2.02 and the portions of Item 99.1 covered by Item 2.02), February 5, 2025, March 4, 2025, May 7, 2025 (except Item 2.02 and the portions of Item 99.1 covered by Item 2.02), May 27, 2025, June 20, 2025, and July 29, 2025; and

    (d) the description of the Common Stock contained in the Registrant’s Registration Statement on Form 20-F filed with the Commission on January 20, 2005 and subsequent Current Report on Form 8-K filed under Rule 12g-3 of the Exchange Act on June 19, 2008, as updated by Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including any amendments or reports filed for the purpose of updating such description.

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the Commission.

     


     

    For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law permits, in general, a Delaware corporation to indemnify any person who was or is a party to any proceeding (other than an action by, or in the right of, the corporation) by reason of the fact that he or she is or was a director or officer of the corporation, or served another business enterprise at the request of the corporation, against liability incurred in connection with such proceeding, including the expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such proceeding, if such person acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, in criminal actions or proceedings, additionally had no reasonable cause to believe that his or her conduct was unlawful. A Delaware corporation’s power to indemnify applies to actions brought by or in the right of the corporation as well, but only to the extent of expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of the action or suit, provided that no indemnification shall be provided in such actions in the event of any adjudication of negligence or misconduct in the performance of such person’s duties to the corporation, unless a court believes that in light of all the circumstances indemnification should apply. Section 145 of the Delaware General Corporation Law also permits, in general, a Delaware corporation to purchase and maintain insurance on behalf of any person who is or was a director or officer of the corporation, or served another entity at the request of the corporation, against liability incurred by such person in such capacity, whether or not the corporation would have the power to indemnify such person against such liability.

     

    The Registrant has entered into indemnification agreements with each of its directors and executive officers and has obtained insurance covering its directors and officers against losses and insuring the Registrant against certain of its obligations to indemnify its directors and officers.

    The Registrant’s Certificate of Incorporation, as amended, provides that the Registrant shall indemnify each of its directors and officers, to the maximum extent permitted from time to time by law, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by reason of the fact that he or she is a director or officer.

    This right of indemnification conferred in the Registrant’s Certificate of Incorporation, as amended, is not exclusive of any other right.

    In addition, the Registrant’s Certificate of Incorporation, as amended, provides that the Registrant’s directors shall not be liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent that the exculpation from liability is not permitted under the Delaware General Corporation Law.

    These indemnification provisions may be sufficiently broad to permit indemnification of the Registrant’s directors and officers for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

     


     

    Exhibit No.

    Description

     

     

    3.1

    Certificate of Incorporation of pSivida Corp. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K12G3 filed with the Commission on June 19, 2008).

     

     

    3.2

    Certificate of Amendment of the Certificate of Incorporation of pSivida Corp. (incorporated herein by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K for the year ended June 30, 2017 filed with the Commission on September 13, 2017).

     

     

    3.3

    Certificate of Correction to Certificate of Amendment of the Certificate of Incorporation of pSivida Corp. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on April 2, 2018).

     

     

    3.4

    Certificate of Amendment of the Certificate of Incorporation, as amended, of EyePoint Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on June 27, 2018).

     

     

    3.5

    By-Laws of EyePoint Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.5 to the Company’s Annual Report on Form 10-K for the year ended June 30, 2018 filed with the Commission on September 18, 2018).

     

     

    3.6

    Amendment No. 1 to By-Laws of EyePoint Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on November 6, 2018).

     

     

    3.7

    Certificate of Amendment of the Certificate of Incorporation of EyePoint Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on June 23, 2020).

     

     

     

    3.8

     

    Certificate of Amendment of the Certificate of Incorporation of EyePoint Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on December 8, 2020).

     

     

     

    4.1

     

    Form of Specimen Stock Certificate for Common Stock (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K12G3 filed with the Commission on June 19, 2008).

     

     

     

    5.1

     

    Opinion of Hogan Lovells US LLP (filed herewith).

     

     

     

    10.1

     

    EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 21, 2023).

     

     

     

    10.2

     

    EyePoint Pharmaceuticals, Inc. Amendment No.1 to 2023 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 21, 2024).

     

     

     

     10.3

     

    EyePoint Pharmaceuticals, Inc. Amendment No. 2 to 2023 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 20, 2025).

     

     

     

     23.1

     

    Consent of Deloitte & Touche LLP, independent registered public accounting firm (filed herewith).

     

     

     

     23.2

     

    Consent of Hogan Lovells US LLP (included in Exhibit 5.1).

     

     

     

     24.1

     

    Power of Attorney (included on signature page hereto).

     

     

     

    FILING FEES

     

    Filing Fee Table (filed herewith).

     

     


     

     

     

     

    Item 9. Undertakings.

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Watertown, Massachusetts, on August 7, 2025.

     

     

     

    EYEPOINT PHARMACEUTICALS, INC.

     

     

    By:

    /s/ Jay S. Duker, M.D.

     

    Jay S. Duker, M.D.

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jay S. Duker, M.D. and Ron Honig, Esq., and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

    Title

    Date

     

     

     

    /s/ Jay S. Duker, M.D.

     President and Chief Executive Officer and Director

    August 7, 2025

    Jay S. Duker, M.D.

    (Principal Executive Officer)

     

     

     

     

    /s/ George O. Elston

    Executive Vice President and Chief Financial Officer

    August 7, 2025

    George O. Elston

    (Principal Financial and Accounting Officer)

     

     

     

     

    /s/ Göran Ando, M.D.

    Chairman of the Board of Directors

    August 7, 2025

    Göran Ando, M.D.

     

     

     

     

     

    /s/ Nancy Lurker

    Vice Chair of the Board of Directors

    August 7, 2025

    Nancy Lurker

     

     

     

     

     

     

    /s/ John B. Landis, Ph.D., M.S.

    Director

    August 7, 2025

    John B. Landis, Ph.D., M.S.

     

     

     

     

     

     

    /s/Wendy DiCicco

    Director

    August 7, 2025

    Wendy DiCicco

     

     

     

     

     

    /s/ Karen Zaderej

    Director

    August 7, 2025

    Karen Zaderej

     

     

     

     

     

     


     

    /s/ Stuart Duty

    Director

    August 7, 2025

    Stuart Duty

     

     

     

    /s/ Fred Hassan

    Director

    August 7, 2025

    Fred Hassan

     

     

     

    /s/ Reginald Sanders, M.D.

    Director

    August 7, 2025

    Reginald Sanders, M.D.

     

     

     

     


    Get the next $EYPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYPT

    DatePrice TargetRatingAnalyst
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    1/7/2025$33.00Buy
    Citigroup
    10/16/2024Sector Outperform
    Scotiabank
    8/28/2024$15.00Buy
    Jefferies
    1/22/2024$35.00Overweight
    JP Morgan
    11/2/2023$20.00Buy
    Mizuho
    4/21/2023$33.00Outperform
    Robert W. Baird
    7/7/2022$21.00Buy
    Chardan Capital Markets
    More analyst ratings

    $EYPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Elston George gifted 20,000 shares and received a gift of 20,000 shares, decreasing direct ownership by 24% to 62,114 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    9/22/25 4:11:05 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Zaderej Karen L. converted options into 2,000 shares, increasing direct ownership by 5% to 38,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    7/11/25 4:07:01 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Duker Jay S. converted options into 16,667 shares and covered exercise/tax liability with 7,688 shares, increasing direct ownership by 911% to 9,965 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    7/11/25 4:06:49 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zaderej Karen L. bought $59,000 worth of shares (10,000 units at $5.90), increasing direct ownership by 38% to 36,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/19/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Zaderej Karen L. bought $54,450 worth of shares (10,000 units at $5.45), increasing direct ownership by 61% to 26,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/15/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dicicco Wendy F bought $19,997 worth of shares (2,567 units at $7.79), increasing direct ownership by 35% to 9,967 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    8/21/24 4:32:51 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

    Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    1/7/25 7:52:05 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on EyePoint Pharmaceuticals

    Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform

    10/16/24 8:38:45 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $EYPT
    SEC Filings

    View All

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 140,600 shares of EyePoint common stock to eight new employees. The stock options were granted on September 15, 2025. The grants were approved by the Compensation Committee and made

    9/16/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Announces Participation at Upcoming Investor Conferences

    WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Citi's 2025 BioPharma Back to School ConferenceForum: Fireside ChatDate: Tuesday, September 2, 2025Time: 2:30 p.m. ET Cantor Global Healthcare ConferenceForum: Fireside ChatDate: Wednesday, September 3, 2025Time: 2:45 p.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference Forum: 1x1 Investor MeetingsDate: Tuesday, September 9, 2025 A live webcast an

    8/26/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 18,000 shares of EyePoint common stock to two new employees. The stock options were granted on August 15, 2025. The grants were approved by the Compensation Committee and made as an ind

    8/18/25 4:01:00 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 filed by EyePoint Pharmaceuticals Inc.

    S-8 - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)

    8/7/25 4:31:23 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by EyePoint Pharmaceuticals Inc.

    10-Q - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)

    8/7/25 4:05:32 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)

    8/6/25 7:05:27 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Leadership Updates

    Live Leadership Updates

    View All

    EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

    WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San

    1/8/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

    WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future

    9/4/24 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

    - Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists

    4/2/24 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Financials

    Live finance-specific insights

    View All

    EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

    – Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuti

    8/6/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

    WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the

    7/30/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

    – Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials expected in 2026 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious

    5/7/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 3:10:08 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 1:22:34 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/12/24 2:31:58 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials